Imovane

Zopiclone, the active ingredient in Imovane, is a cyclopyrrolone presented as a tablet for oral use. It is prescribed for the short‑term management of insomnia in adults. GNH USA supplies Imovane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zopiclone is a sedative‑hypnotic that acts on the central nervous system to treat sleep disorders.

Insomnia (sleep onset): helps reduce the time needed to fall asleep. Insomnia (sleep maintenance): decreases the number of nocturnal awakenings. Transient insomnia due to stress: improves overall sleep quality.

Zopiclone may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Drowsiness or excessive sleepiness. - Dry mouth. - Bitter or metallic taste. - Headache. - Dizziness. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Allergic reactions such as rash, itching, or swelling. - Severe skin reactions (e.g., Stevens‑Johnson syndrome). - Mood changes including depression or suicidal thoughts. - Unusual thoughts or behaviors (e.g., sleep‑walking, hallucinations). - Amnesia or memory impairment. - Respiratory depression when combined with other CNS depressants.

Before prescribing Zopiclone, clinicians should consider several safety factors.

Use in elderly: increased sensitivity to sedative effects, risk of falls. Avoid alcohol: additive central nervous system depression. Renal impairment: dose adjustment may be required. History of depression or mood disorders: monitor for worsening symptoms. Pregnancy and lactation: safety not established; use only if clearly needed. Store at ambient temperature: keep in the original pack, protect from moisture.

Zopiclone can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Alcohol: additive CNS depression leading to profound sedation. - Opioids: increased risk of respiratory depression and profound sedation. - Benzodiazepines: excessive sedation and impaired psychomotor performance.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise plasma concentrations. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Antidepressants (e.g., SSRIs, SNRIs): may increase risk of abnormal thoughts or behaviors.